Reliability of generic quality-of-life instruments in assessing health-related quality of life among children and adolescents with idiopathic nephrotic syndrome: a systematic review

Table 3 Aggregate health-related quality of life (HRQoL) scores in some individual studies

Study authors	Study design	HRQoL score (median or mean/SD score)	HRQoL score (median or mean/SD score)
Selewski et al. [22]	Longitudinal cohort study	68.6 ± 16.0*	73.7 ± 17.8**
Agrawal et al. [17]	Cross-sectional case–control study	65^†, interquartile range = 59–68.75	62.2^††, interquartile range = 58.05–65.78
Khanjari et al. [23]	Prospective case–control study	65.5 ± 12.6^‡	64.6 ± 8.5^‡‡
Khanjari et al. [23]	Prospective case–control study	78.1 ± 8.5^‡	65.1 ± 7.7^‡‡
Roussel et al. [16]	Cross-sectional observational study	76.2 ^¶	72.6 ^¶¶
Roussel et al. [16]	Cross-sectional observational study	71.4 ± 16 ^§	61.6 ± 19.5 ^§§

*Mean score for children with prevalent nephrotic syndrome (disease duration at baseline ≥ 30 days) **Mean score for children with incident nephrotic syndrome (disease duration at baseline < 30 days) ^†Median score for children with nephrotic syndrome ^††Mean score for children with other chronic diseases ^‡Mean scores for children with nephrotic syndrome before and after blended training ^‡‡Mean scores of children with nephrotic syndrome before and after routine interventions ^¶Mean global score for nephrotic patients on oral immunosuppressive drug ^¶¶Mean global score for nephrotic patients on intravenous rituximab ^§Mean score on ‘school functioning domain’ for nephrotic patients on oral immunosuppressive drug ^§§Mean score on ‘school functioning domain’ for nephrotic patients on intravenous rituximab, SD, standard deviation

ISSN: 1477-7525